Investigation of neoadjuvant chemohormonal therapy before robot-assisted radical prostatectomy for the patients with high-risk prostate cancer. - Neoadjuvant chemohormonal therapy for high-risk prostate cancer.

Tottori University Hospital0 sites100 target enrollmentNovember 16, 2018

Overview

No summary available.

Registry

who.int

Start Date

November 16, 2018

End Date

June 6, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

•1\)Patient with the treatment history of docetaxel. 2\)Patient with deep vein thrombosis. 3\)Patient who has the past history of heart failure or myocardial infarction. 4\)Patient with the past history of interstitial pneumonia. 5\)An infectible patient. 6\)Patient with diabetes with difficult control. 7\)Patient who received medication of other investigational drugs within three months before the start of this study. 8\)Patient who already received radiotherapy for prostate cancer. 9\)Patient who is under treatment of other neoplasm except for the prostate cancer now. 10\)Patient who is using the medicine with a possibility that blood concentration may rise by combined use. 11\)Patient who wants to make a child in the future. 12\)In addition, those whom the research responsibility doctor judged to be unsuitable as a research candidate. 13\)Prostate cancer patient who is having hormone therapy already done for six months or more. 14\)Patient who has four or more lymph node metastases in a pelvis. 15\)Patient who has four or more distant metastases.